

**Table S1** Clinical characteristics and outcomes of sarcomatoid cHCC-CC patients

Case	Age (year)	Sex	Operation	CA19-9 (U/mL)	AFP (IU/mL)	Pathology HCC	Pathology ICC	Adjuvant chemotherapy	DFS (months)	OS (months)
#1	48	M	Rt. posterior sectionectomy	N/A	301.78	Edmonson III-IV	Poorly	5FU + carboplatin	4	19
#2	63	M	Segmentectomy, S8	36.7	92.46	Edmonson III-IV	Poorly	Sorafenib	4	10
#3	70	M	Rt. lobectomy	1.5	1,348.9	Edmonson III-IV	Poorly	Sorafenib	33	33
#4	63	M	Rt. anterior sectionectomy	N/A	5.55	Edmonson III	Poorly	N/A	1	5
#5	61	M	Rt. lobectomy	N/A	3.07	Edmonson III-IV	Poorly	Sorafenib	6	24
#6	46	M	Rt. posterior sectionectomy	N/A	11.3	Edmonson III-IV	Poorly	Sorafenib	22	68
#7	58	M	Rt. lobectomy	9.6	2.72	Edmonson III	Undifferentiated	N/A	1	1
#8	67	M	Rt. inferior sectionectomy	N/A	238.8	Edmonson III-IV	Moderately	N/A	1	12
#9	54	M	Lt. lateral sectionectomy	N/A	469.38	Edmonson III-IV	Poorly	Sorafenib	4	5

CA, carbohydrate antigen; AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; DFS, disease-free survival; OS, overall survival; M, male; F, female; N/A, not applicable.